B. Riley Securities Initiates Coverage On Cue Biopharma with Buy Rating, Announces Price Target of $83

B. Riley Securities has initiated coverage on Cue Biopharma (NASDAQ: CUE) with a Buy rating. The analyst, Mayank Mamtani, has set a price target of $83 for the company's stock.